相似文献
1
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.2019 年美国风湿病学会/脊柱关节炎协会/脊柱关节炎研究和治疗网络关于治疗强直性脊柱炎和非放射学中轴型脊柱关节炎的建议更新。
Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22.
2
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.2019 年美国风湿病学会/脊柱关节炎协会/脊柱关节炎研究与治疗网络关于治疗强直性脊柱炎和非放射学中轴型脊柱关节炎的建议更新。
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21.
3
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.美国风湿病学会/脊柱关节炎协会/脊柱关节炎研究和治疗网络 2015 年强直性脊柱炎和非放射学中轴型脊柱关节炎治疗建议。
Arthritis Rheumatol. 2016 Feb;68(2):282-98. doi: 10.1002/art.39298. Epub 2015 Sep 24.
4
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.美国风湿病学会/美国脊柱炎协会/脊柱关节炎研究与治疗网络2015年强直性脊柱炎和非放射学中轴型脊柱关节炎治疗推荐。
Arthritis Care Res (Hoboken). 2016 Feb;68(2):151-66. doi: 10.1002/acr.22708. Epub 2015 Sep 24.
5
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.生物改善病情抗风湿药的疗效与安全性：一项系统性文献综述，为2022年更新的ASAS-EULAR轴性脊柱关节炎管理推荐提供依据
Ann Rheum Dis. 2023 Jan;82(1):130-141. doi: 10.1136/ard-2022-223298. Epub 2022 Oct 21.
6
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?在常规治疗中，使用司库奇尤单抗或肿瘤坏死因子抑制剂治疗的脊柱关节炎患者的前葡萄膜炎：生物治疗的选择是否重要？
Ann Rheum Dis. 2021 Nov;80(11):1445-1452. doi: 10.1136/annrheumdis-2021-220420. Epub 2021 Jun 15.
7
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.司库奇尤单抗与肿瘤坏死因子抑制剂治疗脊柱关节炎的一年疗效：来自五个北欧生物制剂登记处的结果，涵盖超过10,000个治疗疗程
Arthritis Care Res (Hoboken). 2022 May;74(5):748-758. doi: 10.1002/acr.24523. Epub 2022 Mar 8.
8
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.2017 年美国风湿病学会/美国髋膝关节外科医师学会择期全髋关节或全膝关节置换术患者风湿性疾病抗风湿药物围手术期管理指南。
Arthritis Rheumatol. 2017 Aug;69(8):1538-1551. doi: 10.1002/art.40149. Epub 2017 Jun 16.
9
Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.简要报告：未经肿瘤坏死因子阻滞剂治疗的早期非放射性轴性脊柱关节炎和强直性脊柱炎患者的两年临床病程：来自德国脊柱关节炎起始队列的结果。
Arthritis Rheumatol. 2015 Sep;67(9):2369-75. doi: 10.1002/art.39225.
10
Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.用于治疗银屑病关节炎的肿瘤坏死因子（TNF）抑制剂。
Cochrane Database Syst Rev. 2025 Feb 13;2(2):CD013614. doi: 10.1002/14651858.CD013614.pub2.
引用本文的文献
1
Association of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis.低游离T3与强直性脊柱炎疾病存在及活动的关联
Int J Mol Sci. 2025 Aug 14;26(16):7862. doi: 10.3390/ijms26167862.
2
Identification of an IL17RC missense variant in a Chinese family with multiple osteochondromas and ankylosing spondylitis.在中国一个患有多发性骨软骨瘤和强直性脊柱炎的家族中鉴定出一种白细胞介素17受体C（IL17RC）错义变异。
J Hum Genet. 2025 Aug 14. doi: 10.1038/s10038-025-01383-5.
3
Evaluating Secukinumab as Treatment for Axial Spondyloarthritis and Psoriatic Arthritis in Patients with Comorbidities: Multicenter Real-Life Experience.评估司库奇尤单抗治疗合并症患者的中轴型脊柱关节炎和银屑病关节炎：多中心真实世界经验
J Clin Med. 2025 Jul 22;14(15):5181. doi: 10.3390/jcm14155181.
4
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis.异同之处：厘清轴性银屑病关节炎与轴性脊柱关节炎之间的交叉点
Ther Adv Musculoskelet Dis. 2025 Jul 27;17:1759720X251357532. doi: 10.1177/1759720X251357532. eCollection 2025.
5
Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges.强直性脊柱炎领域的突破：创新细胞疗法如何重塑免疫、推动前沿进展并应对未来挑战。
Front Immunol. 2025 Jul 11;16:1613502. doi: 10.3389/fimmu.2025.1613502. eCollection 2025.
6
Effects of a Digital Functional Exercise Program on the Disease Activities and Physical Capabilities of Patients With Ankylosing Spondylitis: Protocol for a Randomized Controlled Trial.数字功能锻炼计划对强直性脊柱炎患者疾病活动度和身体能力的影响：一项随机对照试验方案
JMIR Res Protoc. 2025 Jul 7;14:e67556. doi: 10.2196/67556.
7
Retention rate of TNF inhibitors versus IL-17 inhibitors in ankylosing spondylitis patients with prior biologics experience.有既往生物制剂使用经验的强直性脊柱炎患者中，肿瘤坏死因子抑制剂与白细胞介素-17抑制剂的保留率比较
Arthritis Res Ther. 2025 Jul 4;27(1):135. doi: 10.1186/s13075-025-03601-z.
8
Psychosocial burden of axial spondyloarthritis and impact of different disease domains: a systematic literature review.轴性脊柱关节炎的心理社会负担及不同疾病领域的影响：一项系统文献综述
Rheumatol Adv Pract. 2025 May 26;9(3):rkaf063. doi: 10.1093/rap/rkaf063. eCollection 2025.
9
Understanding and addressing anti-drug antibody formation in tumor necrosis factor-α inhibitor therapy for ankylosing spondylitis.强直性脊柱炎肿瘤坏死因子-α抑制剂治疗中抗药物抗体形成的理解与应对
J Rheum Dis. 2025 Jul 1;32(3):151-153. doi: 10.4078/jrd.2025.0067. Epub 2025 Jun 18.
10
Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis.抗IL-17A单克隆抗体QX002N短期治疗活动性强直性脊柱炎后的安全性、药代动力学、初步疗效、药效学及免疫原性
BMC Pharmacol Toxicol. 2025 May 19;26(1):107. doi: 10.1186/s40360-025-00885-4.
本文引用的文献
1
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.依奇珠单抗，一种白细胞介素-17A 拮抗剂，用于治疗先前未接受生物疾病修饰抗风湿药物（COAST-V）治疗的强直性脊柱炎或放射学中轴型脊柱关节炎患者：一项 3 期随机、双盲、活性对照和安慰剂对照试验的 16 周结果。
Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.
2
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.依奇珠单抗治疗影像学轴向型脊柱关节炎的疗效和安全性：在先前对肿瘤坏死因子抑制剂反应不足或不耐受的患者中进行的一项为期 16 周的 III 期随机、双盲、安慰剂对照试验的结果。
Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8.
3
Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.医疗保险部分 D 下类风湿关节炎依那西普及其生物类似药的自付费用。
JAMA. 2018 Sep 4;320(9):931-933. doi: 10.1001/jama.2018.7316.
4
ACG Clinical Guideline: Management of Crohn's Disease in Adults.ACG 临床指南：成人克罗恩病的管理。
Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27.
5
Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain.健康个体、跑步者和产后腰痛女性的骶髂关节磁共振成像根据脊柱关节炎国际学会的定义评估显示骶髂关节炎。
Arthritis Rheumatol. 2018 Jul;70(7):1042-1048. doi: 10.1002/art.40475. Epub 2018 May 23.
6
Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.TNF-α 抑制剂治疗强直性脊柱炎的疗效比较：系统评价和贝叶斯网状 Meta 分析。
J Rheumatol. 2018 Apr;45(4):481-490. doi: 10.3899/jrheum.170224. Epub 2018 Jan 15.
7
Epidemiology of axial spondyloarthritis: an update.轴向脊柱关节炎的流行病学：最新研究进展。
Curr Opin Rheumatol. 2018 Mar;30(2):137-143. doi: 10.1097/BOR.0000000000000475.
8
A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis.一项研究柳氮磺胺吡啶治疗强直性脊柱炎中轴疾病疗效的随机对照试验。
Int J Rheum Dis. 2018 Jan;21(1):308-314. doi: 10.1111/1756-185X.13124. Epub 2017 Jul 24.
9
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.托法替布治疗溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.
10
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.肿瘤坏死因子抑制剂治疗与强直性脊柱炎前葡萄膜炎的发生：来自瑞典生物制剂登记处的结果。
Ann Rheum Dis. 2017 Sep;76(9):1515-1521. doi: 10.1136/annrheumdis-2016-210931. Epub 2017 Mar 2.
Zotero 插件